NRx Pharmaceuticals, Inc. (NRXP) Earnings Call Transcripts

NRx Pharmaceuticals, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, NRx Pharmaceuticals (NRXP:US) reported a significant reduction in net loss to $1.4 million, or $0.04 per share, compared to a loss of $5.5 million, or $0.34 per share, in the same quarter last year. The company is advancing its KETAFREE product through the FDA review process and expects to launch it in a market facing a ketamine shortage. Management indicated that they have sufficient cash for operations and raised $7 million post-quarter end, signaling strong financial positioning as they prepare for product launches and clinical trials.

Reported metrics

Guidance from management

Management indicated that cash resources and anticipated growth in clinic operations will support operations through at least 2026. They also expect to have at least 1 million units of KETAFREE available at launch.

What management said

Well, there are some regulatory costs involved. So we're expecting FDA to put [ back ] to us approximately by the end of the month. I don't want to give you an exact date, but I don't have it at my fingertips, but that's about the time frame.

It's not an issue for us. Availability of raw material is not a problem. I can't tell you the exact situation with pharmaceutical grids last today. I can tell you that during COVID, people were backed up a year. Pharmaceutical glass is kind of a problem worldwide.

What analysts pressed on

Analysts expressed concerns regarding the operational challenges of KETAFREE distribution channels and the reliance on compounding pharmacies due to the current ketamine shortage. There were also questions about the clarity of FDA requirements for the real-world evidence data.

Main topics on the call

• KETAFREE FDA Progress — NRx is nearing the completion of the FDA review for KETAFREE, with a goal for approval by summer 2026. Management stated, "Leadership of the FDA Office of Generic Drugs expressed support for addressing the remaining item...
• Debt-Free Status — The company has eliminated its debt, stating, "Now we are debt free," which enhances its financial flexibility for future growth initiatives.
• NRX-100 NDA Submission — Management confirmed that the NDA for NRX-100 is on track for submission in the second quarter of 2026, supported by real-world evidence from over 65,000 patients. This aligns with the FDA's recent encouragement for usin...
• MIND1 Trial Initiation — The MIND1 trial for NRX-101 has received FDA clearance to proceed, with expectations of significant funding support. The trial aims to enroll 400 participants and could potentially lead to a registration-enabling outcome...

Read the full NRx Pharmaceuticals, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 23 NRx Pharmaceuticals, Inc. earnings call transcripts on record, spanning November 14, 2022 to August 10, 2026. Based on this history, NRx Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NRXP

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

23

First call

November 14, 2022

Most recent

August 10, 2026

Reporting cadence

quarterly